Alternative Blood Test More Effective for Guiding Heart Disease Treatment
Research indicates that apolipoprotein B testing outperforms standard LDL cholesterol tests in predicting risk and guiding therapy.
Research indicates that apolipoprotein B testing outperforms standard LDL cholesterol tests in predicting risk and guiding therapy.
Data from nearly 1,900 SEER-linked patients show the test identifies meaningful survival differences within the same AJCC stage.
As the 2026 ADA Standards of Care emphasize earlier identification and more precise classification of diabetes, clinical laboratories are rethinking workflows, assay menus, and their role in detection.
A new study validates a machine-learning platform that detects prostate cancer through biochemical patterns in urine samples.
Research identifies how circulating tumor DNA can inform personalized treatment and surveillance strategies.
The NIH has awarded $850,000 to Northwell Health’s Feinstein Institutes to advance a noninvasive menstrual blood test for endometriosis, aiming to reduce reliance on surgical diagnosis, according to the institutes.
Researchers at JAX and MIT have developed a microneedle patch that samples immune cells from skin within hours, providing a noninvasive alternative to blood draws and biopsies.
The ACC, AHA, and nine other associations have issued an updated dyslipidemia guideline, recommending earlier intervention and expanded use of lipoprotein(a) and apolipoprotein B testing to improve cardiovascular risk assessment.
Researchers at the University of East Anglia report that gut-derived blood markers may help detect early cognitive decline before symptoms, according to findings published in Gut Microbes.
Researchers at UC San Diego have developed the MAPI score, a blood test using five standard lab values to distinguish alcohol-related liver injury from metabolic causes, according to a study in Gastroenterology.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A multicenter, vignette-based study found that adding a rapid sepsis test result to standard clinical data changed or reinforced diagnostic decisions in 86% of cases.